One-Year Outcomes of the Treat-and-Extend Approach with Aflibercept in Age-Related Macular Degeneration: Effects on Typical Choroidal Neovascularization and Retinal Angiomatous Proliferation
One-Year Outcomes of the Treat-and-Extend Approach with Aflibercept in Age-Related Macular Degeneration: Effects on Typical Choroidal Neovascularization and Retinal Angiomatous Proliferation
复制标题
DOI：
10.1159/000453281
复制
发表时间：
2016-01-01
期刊：
影响因子：
2.6
通讯作者：
Navarro-Palop, Catalina
中科院分区：
文献类型：
--
作者：
Castro-Navarro, Veronica;Cervera-Taulet, Enrique;Navarro-Palop, Catalina
目的：探讨阿柏西普治疗延长方案（TER）对渗出性年龄相关性黄斑变性（AMD）继发的典型脉络膜新生血管（CNV）和视网膜血管瘤增殖（RAP）的功能/形态学结果。方法：这是一项根据 TER 方案使用 2 mg 阿柏西普治疗 37 只眼睛的回顾性研究。检查包括最佳矫正视力 (BCVA)、注射次数和所需就诊。此外，在基线以及 3、6 和 12 个月时进行了荧光素血管造影和谱域光学相干断层扫描的定量/定性分析。结果：BCVA 从 0.6 +/- 0.27 logMAR 显着改善至 0.4 +/- 0.34 logMAR。典型 CNV 和 RAP 或非典型 CNV 的最终平均注射次数分别为 8.03 +/- 1.27 和 7.28 +/- 0.75，就诊次数分别为 6.5 +/- 1.09 和 7.14 +/- 1.57，并且不同 CNV 亚型之间没有差异 (p > 0.05)。结论：TER 中的阿柏西普对所有渗出性 AMD 亚型均有效。患者的视力增益、平均注射次数和所需就诊次数并不取决于 CNV 的亚型。 (C) 2016 S. Karger AG，巴塞尔
Objective: To investigate functional/morphological outcomes of the treat-and-extend regimen (TER) with aflibercept in typical choroidal neovascularization (CNV) and retinal angiomatous proliferation (RAP) secondary to exudative age-related macular degeneration (AMD). Methods: This was a retrospective study of 37 eyes treated with 2 mg aflibercept according to a TER protocol. Examinations included best corrected visual acuity (BCVA), numbers of injections, and visits needed. Additionally, quantitative/qualitative analyses with fluorescein angiography and spectral domain optical coherence tomography were conducted at baseline as well as at 3, 6, and 12 months. Results: BCVA significantly improved from 0.6 +/- 0.27 to 0.4 +/- 0.34 logMAR. The final mean numbers of injections were 8.03 +/- 1.27 and 7.28 +/- 0.75 and the numbers of visits 6.5 +/- 1.09 and 7.14 +/- 1.57 in typical CNV and in RAP or atypical CNV, respectively, and they did not differ between the different subtypes of CNV (p > 0.05). Conclusions: Aflibercept in TER is effective for all exudative AMD subtypes. The patient's visual gain, the mean number of injections, and the number of visits needed did not depend on the subtype of CNV. (C) 2016 S. Karger AG, Basel